A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers From Obese Subjects

NCT02062255 EARLY_PHASE1 COMPLETED

Obesity promotes worse outcome for post-menopausal breast cancer patients.

Details

Lead sponsor	The University of Texas Health Science Center at San Antonio
Phase	EARLY_PHASE1
Status	COMPLETED
Enrolment	126
Start date	2013-10
Completion	2016-04

Conditions

• Breast Cancer Survivors

Interventions

• Aspirin
• Omega 3 FFA

Primary outcomes

• Biomarker levels — 29 days
  Blood levels of Prostaglandin E2, aromatase, pro-inflammatory cytokines, steroids, and lipids will be measured pre and post treatment.

Countries

United States